Physician profile
David J Silber
NPI 1760748537
$2,634.04
in general payments reported to CMS, 2019-2025
15 companies · $565 in 2025
The $565 reported for 2025 was less than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $812 · 2020: $169 · 2021: $292 · 2022: $266 · 2023: $124 · 2024: $407 · 2025: $565.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,031 · Education: $64.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,030.74 |
| Education | $64.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $928.03 | 2019-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Ancora Heart, INC. | $793.91 | 2019-2025 | Accucinch |
| Pfizer INC. | $141.33 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $137.98 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $134.47 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $121.37 | 2025 | Winrevair |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $69.87 | 2019 | |
| Boston Scientific Corporation | $67.83 | 2023-2024 | |
| Actelion Pharmaceuticals US, INC. | $64.99 | 2023 | Uptravi, Opsumit |
| United Therapeutics Corporation | $63.31 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $28.33 | 2024 | Camzyos |
| Novartis Pharmaceuticals Corporation | $27.14 | 2019-2020 | |
| Abiomed | $24.59 | 2025 | |
| Alnylam Pharmaceuticals INC. | $17.99 | 2025 | Amvuttra |
| Amarin Pharma, INC. | $12.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Silber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.